Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients;Ensayo clínico aleatorizado para evaluar tres pautas cortas de tratamiento de la infección latente tuberculosa en pacientes infectados por el VIH

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 25, Issue 5, 2007, Pages 305-310

  Rivero, Antonio ^a   López Cortés, Luis ^b   Castillo, Rafael ^c   Verdejo, José ^d   García, Miguel Ángel ^e   Martínez Marcos, Francisco Javier ^b   Díez, Felipe ^f   Escribano, José Carlos ^g   Canueto, Jesús ^h   Lozano, Fernando ⁱ   Pasquau, Juan ^j   Hernández, Juan José ^k   Márquez, Manuel ^l   Kindelán, José María ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^f HOSPITAL TORRECÁRDENAS   (Spain)

^g HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^h Hospital Punta Europa de Algeciras   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^k Hosp Univ Ciudad de Jaén   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

more..

Author keywords

Chemoprophylaxis; HIV; Latent tuberculosis infection; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SKIN TEST; TUBERCULIN TEST; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 34547631472     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13102265     Document Type: Article

References (31)

1. Gallant JE, Moore RD, Chaisson RE. Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med. 1994;120:932-44.
2. Moreno S, Cobo J. Las múltiples caras del control de la tuberculosis. Enferm Infecc Microbiol Clin. 2003;21:279-80.
3. Bran C, Gómez i Prat J, Cayla JA, García de Olalla P. Factors associated with latent tuberculous infection in immigrants less than 35 years old. Enferm Infecc Microbiol Clin. 2006;24:322-5.
4. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression on HIV infection. Lancet. 1993;342:268-72.
5. Whalen CC, Johnson JL, Okwera A, Hom DL, Huebner R, Mugyenyi P, et al. A trial of three regimens to prevent tuberculosis in ugandan adults infected with the human immunodeficiency virus. N Engl J Med. 1997;337:801-8.
6. Mwinga AG, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998;12:2447-57.
7. Hawken MP, Meme HK, Elliot LC, Chakaya JM, Morris JS, Githui WA, et al. Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS. 1997;11:875-82.
8. WHO. Preventive Therapy againts tuberculosis in people living with HIV. Weekly Epidemiological Record. 1999;74:46.
9. Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13:501-7.
10. Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320:545-50.
11. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS. 1993;7:1345-9.
12. Graham MNH, Galai N, Nelson KE, Astemborski J, Bonds M, Rizzo R, et al. Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. Arch Intern Med. 1996;156:889-94.
13. Garzaro P, Herchline TE. Completion rates for preventive therapy for the Montgomery county combined health district tuberculosis clinic for the years 1988-1990 and 1995-97. En 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998, September 24-27, San Diego, USA (Abstract L-23).
14. Gordin F, Chaisson RE, Miller C, García ML, Hafner R, Valdespino JL, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons. An international randomized trial. JAMA. 2000;283:1445-50.
15. Centers for Disease Control and Prevention (CDC). Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR. 1998;47(RR-20):1-58.
16. Jasmer RM, Saukkonen JJ, Blumberg HM, Daley CL, Bernardo J, Vittinghoff E, et al, for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators. Short-Course Rifampin and Pyrazinamide Compared with Isoniazid for Latent Tuberculosis Infection: A Multicenter Clinical Trial. Ann Intern Med. 2002;137:640-7.
17. Centers for Disease Control and Prevention (CDC). Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC Recomendations. United States, 2001. MMWR. 2001;50:733-5.
18. De March-Ayuela P, García A. La evolución de la infección VIH/SIDA en los países desarrollados. Impacto sobre la tuberculosis. Med Clin (Barc). 1993;100:187-93.
19. a ed. Sevilla: Consejería de Salud; 2003. p. 37-54.
20. Pulido F, Iribarren JA, Kindelán JM, Moreno S. Diagnóstico y tratamiento de infecciones por micobacterias en pacientes con VIH/sida. Enferm Infecc Microbiol Clin. 1998;16 Supl 1: 20-8.
21. Halsey NA, Coberly JS, Desormeaux J, Losikoff P, Atkinson J, Moulton LH, et al. Randomized trial of isoniazid versus rifampicin and pyrazynamide for prevention of tuberculosis in HIV infection. Lancet. 1998;351:786-92.
22. Rivero A, López-Cortés L, Castillo R, Lozano F, García MA, Díez F, et al. Ensayo clínico aleatorizado de tres pautas de quimioprofilaxis para prevenir tuberculosis en pacientes infectados por el VIH con anergia cutánea. Enferm Infecc Microbiol Clin. 2003;21:287-92.
23. Ferebee S. Controlled chemoprophylaxis trials in tuberculosis: a general review. Adv Tuberc Res. 1970;17:28-106.
24. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull WHO. 1982;60:555-64.
25. Martínez E, Cuadra F, Solera J, Maciá MA, Geijo P, Sánchez PA, et al. Evaluación de dos pautas de QP tuberculosa en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Barc). 2000;115:161-5.
26. Álvarez-Mcleod AP, Walpole A, Fochler P. Two months of Rifampin (RIF) and Pyrazinamide (PZA) improve completion rate of tuberculosis (TB) infection treatment in a suburban Atlanta jail. En 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000, September 17-20, Toronto, Canada (Abstract 1580).
27. Herchline TE, Miller MK. Targeted short course regimens improve adherence for the treatment of latent tuberculosis. En 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000, September 17-20, Toronto, Canada (Abstract 1583).
28. Bock N, Rogers T, Tapia J, Herron G, DeVoe B, Geiter L. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest. 2001;119:833-7.
29. Portilla J, Jordá P, Esteban J, Sánchez-Payá J, Merino E, Boixe V, y Grupo de Estudio Protocolo-INH. Tratamiento directamente observado de la infección tuberculosa latente: estudio comparativo de dos pautas con isoniazida. Enferm Infecc Microbiol Clin. 2003;21:293-5.
30. Rivero A, Márquez M, Santos J, Pinedo MA, Esteve A, Samper S, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis. 2001;32:159-61.
31. Samper S, Martín C, Pinedo A, Rivero A, Blázquez J, Baquero F, et al. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. AIDS. 1997;11:1237-42.